Robert Gold, University of California Riverside; Disney lobbies Congress to change copyright laws
"Copyright law is a tedious topic but it affects people in their daily lives."
Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD
Showing posts with label lobbying. Show all posts
Showing posts with label lobbying. Show all posts
Wednesday, February 13, 2019
Tuesday, July 11, 2017
Why drugmakers aren’t sweating the next wave of patent losses; Bloomberg News via News Chief, July 10, 2017
Bloomberg News via News Chief; Why drugmakers aren’t sweating the next wave of patent losses
"Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.
"Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.
The loss of a series of key patents for cholesterol fighters and other widely used medicines cost big-name drug companies about $82 billion in sales between 2011 and 2013, according to life-sciences data company Evaluate Ltd., forcing large-scale job cuts and a wave of deals to make up for lost revenue...
By the time lawmakers passed a path to market for biosimilars as part of the Affordable Care Act in 2010, the industry had assured that competition would come much more slowly, making the resulting sales decline look less like a precipice and more like a gentle hill."
Subscribe to:
Posts (Atom)